Herantis Pharma Plc announced Results of proof-of-concept study demonstrating successful nanoforming of HER-096 into nanoparticles and further exploration the applicability of Nanoform's technology in the development of an oral dosage form based on HER-096 nanoparticles. Herantis has previously shown that HER-096 penetrates the blood brain barrier and enters the brain in therapeutic concentrations in healthy rats following subcutaneous administration. Subcutaneous administration will be used in Herantis' HER-096 first-in-human clinical study that is expected to commence in 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.45 EUR | +1.05% | +0.69% | -7.94% |
03-06 | Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-06 | Transcript : Herantis Pharma Oyj, 2023 Earnings Call, Mar 06, 2024 |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.94% | 31.23M | |
+4.11% | 111B | |
+11.47% | 105B | |
-13.00% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.24% | 16.96B | |
+3.27% | 13.7B | |
+36.96% | 12.45B |
- Stock Market
- Equities
- HRTIS Stock
- News Herantis Pharma Oyj
- Herantis Pharma Plc Announces Successful HER-096 Initial Results with Nanoform Technology